Distributor inventory | Tablet

Management of type 2 diabetes mellitus to reduce post‑meal (postprandial) blood glucose; used alone or with other antidiabetic medicines along with diet and exercise.

Voglibose is an alpha‑glucosidase inhibitor that delays breakdown and absorption of carbohydrates in the small intestine. This reduces the rise in blood glucose after meals.

Take by mouth just before meals (typically immediately before the first bite of food) as prescribed by the doctor. If you skip a meal, skip the dose. Continue diet and exercise advice; monitor blood sugar regularly.

Flatulence, abdominal pain, diarrhea, bloating, nausea

Not for type 1 diabetes or diabetic ketoacidosis. Use with caution in kidney or liver disease and in elderly patients. Avoid/use caution in inflammatory bowel disease, colonic ulceration, intestinal obstruction or predisposition to obstruction. Risk of hypoglycaemia increases when used with insulin or sulfonylureas—carry glucose (dextrose) for treatment as sucrose absorption may be delayed. Seek medical help for severe abdominal pain, persistent diarrhea, or signs of liver injury (yellowing of eyes/skin, dark urine).

Insulin, sulfonylureas (e.g., glimepiride/gliclazide) may increase hypoglycaemia risk; digestive enzyme preparations (amylase/pancreatin) may reduce effect; intestinal adsorbents may reduce effect; other antidiabetics may have additive glucose-lowering.

Store below 25°C in a dry place, protected from light and moisture. Keep in original blister pack and out of reach of children.

Voglib 0.3 Tablet, Vobit 0.3 Tablet, Volibo 0.3 Tablet, Vogly 0.3 Tablet, Voglitor 0.3 Tablet